Advertisement


Jean-Charles Soria, MD, PhD, on Results of the KEYNOTE 001 Clinical Trial

2015 European Cancer Congress

Advertisement

Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: the efficacy and safety of pembrolizumab in previously treated non-small cell lung cancer (Abstract LBA33).



Related Videos

Lung Cancer

M. Catherine Pietanza, MD, on A Promising New Agent for SCLC

M. Catherine Pietanza, MD, of Memorial Sloan Kettering Cancer Center, discusses rovalpituzumab tesirine, a promising DLL3-targeted antibody drug conjugate, the first precision treatment for small cell lung cancer (Abstract 7LBA).

Leukemia
Lymphoma

Michael Pfreundschuh, MD, on Treating Lymphoid Malignancies in Children and Adults With the Same Protocols

Michael Pfreundschuh, MD, of Universitaetsklinikum des Saarlandes, summarizes a session he chaired on this topic, which covered Burkitt’s lymphoma as well as lymphoblastic leukemia in children and adults.

Lung Cancer

Jean-Yves Douillard, MD, PhD, on New Perspectives in Small Cell Lung Cancer

Jean-Yves Douillard, MD, PhD, of Centre R Gauducheau, reviews new clinical trials and data on systemic and radiation treatment of small cell lung cancer.

Breast Cancer

Lisa Carey, MD, on Molecular Screening for Breast Cancer

Lisa Carey, MD, of the University of North Carolina, discusses heterogeneity, treatment response, and outcome in HER2-positive breast cancer.

Kidney Cancer

Toni K. Choueiri, MD, on Cabozantinib vs Everolimus in Patients With Advanced Renal Cell Carcinoma

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses results of the phase III METEOR trial in advanced renal cell carcinoma, which evaluated the efficacy of cabozantinib compared to everolimus in patients with disease progression after VEGFR-targeted therapy (Abstract 4LBA).

Advertisement

Advertisement




Advertisement